Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Goodwill & Intangibles: 2010-2025

Historic Goodwill & Intangibles for Ligand Pharmaceuticals (LGND) over the last 14 years, with Sep 2025 value amounting to $335.1 million.

  • Ligand Pharmaceuticals' Goodwill & Intangibles fell 11.86% to $335.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $335.1 million, marking a year-over-year decrease of 11.86%. This contributed to the annual value of $371.9 million for FY2024, which is 7.71% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Goodwill & Intangibles stood at $335.1 million for Q3 2025, which was down 4.72% from $351.7 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Goodwill & Intangibles registered a high of $774.3 million during Q1 2021, and its lowest value of $318.6 million during Q3 2023.
  • Over the past 3 years, Ligand Pharmaceuticals' median Goodwill & Intangibles value was $380.2 million (recorded in 2024), while the average stood at $379.6 million.
  • Data for Ligand Pharmaceuticals' Goodwill & Intangibles shows a peak YoY increase of 157.36% (in 2021) and a maximum YoY decrease of 52.01% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Ligand Pharmaceuticals' Goodwill & Intangibles stood at $376.7 million in 2021, then declined by 9.09% to $342.5 million in 2022, then climbed by 17.67% to $403.0 million in 2023, then declined by 7.71% to $371.9 million in 2024, then declined by 11.86% to $335.1 million in 2025.
  • Its Goodwill & Intangibles stands at $335.1 million for Q3 2025, versus $351.7 million for Q2 2025 and $359.9 million for Q1 2025.